Hexarelin research and evidence overview

Hexarelin's human evidence base is real but very small: a handful of physiology studies in single-digit or low-double-digit numbers of volunteers, run mostly in the 1990s and early 2000s, measuring hormone levels rather than clinical outcomes. Its more distinctive research line—cardiovascular effects mediated by CD36 rather than the ghrelin receptor—is almost entirely preclinical. Development stopped short of an approved indication, so there are no phase 3 trials, no long-term safety dataset, and no outcome data in people.

What the literature does contain is unusually informative about hexarelin's limits, because the key human trial was designed to look for exactly the problem that constrains the compound.

Hexarelin is a synthetic hexapeptide that activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin uses, and it is chemically more stable and more potent than ghrelin itself (PMID 25278975).

Its potency was substantial enough that clinicians tested it as a diagnostic agent. In a study of 19 patients with suspected pituitary disease (PMID 10469018), intravenous hexarelin at 2 µg/kg was compared head-to-head with the insulin tolerance test, the reference standard. Peak GH was markedly higher after hexarelin (67.1 ± 16 vs 26.9 ± 6.8 mU/L, p<0.001) while peak cortisol was lower (420 ± 34 vs 605 ± 50 nmol/L, p<0.001), and responses to the two tests correlated closely. Every patient with a subnormal GH response to hexarelin also failed the insulin tolerance test. This is a diagnostic application in a clinical population—not evidence about the effects of repeated use in healthy people.

The single most important human hexarelin study for anyone reading marketing claims is a randomized controlled trial in European Journal of Endocrinology (PMID 11888836). Six healthy young men received subcutaneous hexarelin at 1.5 µg/kg either two or three times daily, with blood sampled every 20 minutes across 24 hours and analyzed by deconvolution.

• Both schedules raised mean and 24-hour integrated GH to the same extent—three injections gave no advantage over two.
• The increase came from larger GH secretory bursts, not more of them, and daily GH production rate rose.
• IGF-1 did not change. Neither did prolactin, ACTH, or cortisol secretion across the day.
• When an intravenous hexarelin challenge was given at the end of each 24-hour profile, prior exposure blunted the GH response and abolished the ACTH and cortisol responses entirely.

Two conclusions follow. First, tachyphylaxis is not a theoretical concern—it was measured directly within a single day of repeated dosing. Second, GH concentrations rising without a corresponding IGF-1 rise means that the headline pharmacological effect did not translate into the downstream signal most anabolic claims depend on. Single-dose provocative studies, which is what most of the hexarelin literature consists of, cannot be read as evidence about sustained use.

Hexarelin's cardiovascular research follows a separate mechanism. Investigators labeled rat cardiac membranes with a photoactivatable hexarelin derivative and purified the binding protein, identifying it by N-terminal sequencing as CD36, a glycoprotein expressed in cardiomyocytes and microvascular endothelial cells (Circulation Research, 2002; PMID 11988484). In perfused hearts, hexarelin raised coronary perfusion pressure dose- dependently—an effect absent in hearts from CD36-null mice and from spontaneously hypertensive rats that are genetically CD36-deficient.

Worth reading carefully: the observed effect in that experiment was coronary vasoconstriction, which the authors linked to the coronary vasospasm seen in hypercholesterolemia and atherosclerosis. Later work has explored cardioprotective effects through the same receptor (PMID 25278975), and the direction of the net cardiovascular effect appears to depend on model and context. All of this is animal and isolated-organ work. Human cardiovascular outcome data for hexarelin does not exist.

Three things distinguish an informative hexarelin paper: species (most cardiovascular findings are rat), dosing duration (single-bolus GH responses behave very differently from repeated dosing), and whether IGF-1 was measured alongside GH. Claims built on acute GH spikes in provocative testing are citing a real measurement in a context that does not describe ongoing use.